Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

NCT01445795 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: 200 mg INX-08189 Fasted
DRUG: Placebo QD Fasted
DRUG: 100 mg INX-08189 QD
DRUG: Placebo QD
DRUG: 100 mg INX-08189 with low-fat meal
DRUG: Placebo with low-fat meal
DRUG: 100 mg INX-08189 BID Fasted
DRUG: Placebo BID Fasted
DRUG: ribavirin

Sponsor

Bristol-Myers Squibb